Rhythm Pharmaceuticals (RYTM) Equity Average (2017 - 2026)

Rhythm Pharmaceuticals (RYTM) has 10 years of Equity Average data on file, last reported at $131.0 million in Q1 2026.

• Equity Average for Q1 2026 came in at $131.0 million, up 544.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $131.0 million (up 544.05% YoY), and the FY2025 annual result was $80.4 million, down 16.03% from the prior year.
• Equity Average retreated to $131.0 million in Q1 2026 per RYTM's latest filing, from $143.9 million in the prior quarter.
• Over five years, Equity Average peaked at $272.7 million in Q4 2022 and troughed at $3.5 million in Q2 2025.
• A 5-year average of $139.9 million and a median of $143.9 million in 2025 frame the typical range for Equity Average.
• On a YoY basis, Equity Average climbed as much as 773.86% in 2025 and fell as far as 93.03% in 2025.
• A 5-year view of Equity Average shows it stood at $272.7 million in 2022, then sank by 32.67% to $183.6 million in 2023, then tumbled by 91.03% to $16.5 million in 2024, then surged by 773.86% to $143.9 million in 2025, then retreated by 9.0% to $131.0 million in 2026.
• Business Quant data shows RYTM's Equity Average at $131.0 million in Q1 2026, $143.9 million in Q4 2025, and $68.5 million in Q3 2025.